Embolic Protection Device Clinical Trial Analysis

Summary

Global Markets Direct's "Embolic Protection Device Clinical Trials Analysis" is an essential source of data and information pertaining to product clinical trials being carried out by Embolic Protection Device manufacturers, globally. The report provides exhaustive information on each clinical investigation study with coverage detailed coverage on the pipeline products these trials are being carried out for.

Scope

• The report provides analysis and review of the key clinical trials being carried out globally and across key Embolic Protection Device market categories - Embolic Protection Device
• The report covers information on each product being clinically tested with detailed coverage on the pipeline product profile, the indication it's being investigated for etc.
• The report provides an in-depth analysis of the clinical trials with information on trial phase, trial 0status, trial acronym, purpose, inclusion and exclusion criteria, description, design, intervention, investigator information, primary and secondary end-points and trial results
• The report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by Global Markets Direct's team of industry experts.

Reasons to Buy

• Effectively plan your Mergers and Acquisitions and partnership strategies by identifying companies with the most promising pipeline.
• Stay ahead of the information curve in the fast changing Embolic Protection Device market.
• Plan in-licensing and out-licensing opportunities through review of pipeline products and technologies.
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Proactively plan and execute your competitive strategies by identifying clinical trials status of the leading competitive products in pipeline.
• Stay ahead of competition by understanding the changing competitive landscape in specific geographies.

Contents

• 1 List of Tables
• 1.2 List of Figures
• 2 Embolic Protection Device Clinical Trials
  • 2.1 Embolic Protection Device Clinical Trial By Equipment Type
  • 2.2 Embolic Protection Device Clinical Trials By Trial Phase and Trial Status
  • 2.3 Embolic Protection Device Pipeline Products By Development Stage
  • 2.4 Embolic Protection Device Pipeline Products By Therapy Area
  • 2.5 Embolic Protection Device Pipeline Products By News Summary
  • 2.6 Embolic Protection Device MO.MA
    • 2.6.1 DESERVE: Diffusion Weighted-MRI Based Evaluation Of The Effectiveness Of Endovascular Clamping During Carotid Artery Stenting With The Mo.Ma Device A Prospective, Multicenter Study
    • 2.6.2 Effect Of Two Different Neuroprotection Systems On Microembolization During Carotid Artery Stenting
    • 2.6.3 ARMOUR: Proximal Protection With The MO.MA Device During Carotid Stenting
  • 2.7 Embolic Protection Device Emboshield Pro Rapid Exchange Embolic Protection System Generation
    • 2.7.1 PROTECTed Carotid Artery Stenting in Subjects at High Risk for Carotid Endarterectomy (CEA)
    • 2.7.2 Carotid Angioplasty And Stenting Versus Endarterectomy In Asymptomatic Subjects Who Are At Standard Risk For Carotid Endarterectomy With Significant Extracranial Carotid Stenotic Disease
  • 2.8 Embolic Protection Device GORE Embolic Filter
    • 2.8.1 EMBOLDEN Clinical Study
  • 2.9 Embolic Protection Device FiberNet Distal Protection System
    • 2.9.1 Fibernet Renal Artery Embolic Protection Study: A Prospective, Single-Arm Feasibility Trial Of Renal Artery Distal Protection Using The Lumen Biomedical Fibernet Embolic Protection System
• 3 Recent Developments
  • 3.1 Product News
    • 3.1.1 Jun 12, 2009: Abbott Launches Emboshield NAV6 Embolic Protection System
    • 3.1.2 Mar 10, 2009: GORE Flow Reversal System Treats First Patient At Hahnemann University Hospital
    • 3.1.3 Feb 09, 2009: Gore Receives 510 (k) Clearance For GORE Flow Reversal System
    • 3.1.4 Jan 16, 2009: First Patient Enrolled In W.L. Gore & Associates' Gore EMBOLDEN Clinical Study
    • 3.1.5 Dec 31, 2008: INVATEC's New Mo.Ma Ultra Introduced At ICCA 08, Frankfurt
    • 3.1.6 Nov 19, 2008: Lumen Biomedical's FiberNet Embolic Protection System Receives FDA Approval For Carotid Artery Stenting
    • 3.1.7 Oct 16, 2008: EPIC Carotid Stent Trial Reveals Lowest Sroke Rates With Distal Protection To Date
    • 3.1.8 Oct 15, 2008: Lumen Biomedical To Present EPIC Carotid Stenting Trial At TCT Conference
    • 3.1.9 Oct 10, 2008: W. L. Gore & Associates Receives FDA Approval For Gore EMBOLDEN Clinical Study
    • 3.1.10 Jul 25, 2007: St. Jude Medical Announces FDA Clearance Of The Proxis Embolic Protection System
  • 3.2 Product Approvals
    • 3.2.1 Feb 09, 2009: Gore Receives 510 (k) Clearance For GORE Flow Reversal System
    • 3.2.2 Nov 19, 2008: Lumen Biomedical's FiberNet Embolic Protection System Receives FDA Approval For Carotid Artery Stenting
  • 3.3 Clinical Trials
    • 3.3.1 Jan 16, 2009: First Patient Enrolled In W.L. Gore & Associates' Gore EMBOLDEN Clinical Study
    • 3.3.2 Oct 16, 2008: EPIC Carotid Stent Trial Reveals Lowest Sroke Rates With Distal Protection To Date
    • 3.3.3 Oct 15, 2008: Lumen Biomedical To Present EPIC Carotid Stenting Trial At TCT Conference
    • 3.3.4 Oct 10, 2008: W. L. Gore & Associates Receives FDA Approval For Gore EMBOLDEN Clinical Study
• 4 Appendix
  • 4.1 Methodology
    • 4.1.1 Coverage
    • 4.1.2 Secondary Research
    • 4.1.3 Primary Research
    • 4.1.4 Expert Panel Validation
  • 4.2 Contact Us
  • 4.3 About Global Markets Direct
  • 4.4 Disclaimer
• 1 List of Tables
  • Table 1: Embolic Protection Device Clinical Trial By Equipment Type
  • Table 2: Embolic Protection Device Clinical Trials By Trial Phase and Trial Status
  • Table 3: Embolic Protection Device Pipeline Products By Development Stage
  • Table 4: Embolic Protection Device Pipeline Products By Therapy Area
  • Table 5: Embolic Protection Device Pipeline Products By News Summary
  • Table 6: MO.MA - DESERVE: Diffusion Weighted-MRI Based Evaluation Of The Effectiveness Of Endovascular Clamping During Carotid Artery Stenting With The Mo.Ma Device A Prospective, Multicenter Study
  • Table 7: MO.MA - Effect Of Two Different Neuroprotection Systems On Microembolization During Carotid Artery Stenting
  • Table 8: MO.MA - ARMOUR: Proximal Protection With The MO.MA Device During Carotid Stenting
  • Table 9: Emboshield Pro Rapid Exchange Embolic Protection System Generation 5 - PROTECTed Carotid Artery Stenting in Subjects at High Risk for Carotid Endarterectomy (CEA)
  • Table 10: Emboshield Pro Rapid Exchange Embolic Protection System Generation 5 - Carotid Angioplasty And Stenting Versus Endarterectomy In Asymptomatic Subjects Who Are At Standard Risk For Carotid Endarterectomy With Significant Extracranial Carotid Stenotic Disease
  • Table 11: GORE Embolic Filter - EMBOLDEN Clinical Study
  • Table 12: FiberNet Distal Protection System - Fibernet Renal Artery Embolic Protection Study: A Prospective, Single-Arm Feasibility Trial Of Renal Artery Distal Protection Using The Lumen Biomedical Fibernet Embolic Protection System
• 1.2 List of Figures
  • Figure 1: Global Markets Direct Methodology